IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...
IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has been given a consensus rating of “Reduce” by the ten brokerages that are covering the stock, Ratings reports. One equities research analyst ...
9d
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.
Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, ...
Prof. Colin Parrish, the John Olin Professor of Virology at the Baker Institute for Animal Health, has been elected to the American Academy of Microbiology. This prestigious nomination puts him among ...
Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...
Red cell alloantibodies are primarily IgG and less often IgM. IgM antibodies readily fix complement and it is these that classically cause the intravascular AHTR. IgG antibodies typically cause ...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...
When this method was applied to WGS data it revealed that B cells producing IgM/D antibodies in the blood (produced when the body first encounters a foreign antigen) were the only type of B cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback